# Lecture 6: Thyroid Nodules and Cancer
## Unit 2.3: Endocrine System
---
## Learning Objectives
By the end of this lecture, students will be able to:
1. Describe the epidemiology and evaluation of thyroid nodules
2. Explain the role of ultrasound and fine-needle aspiration in nodule assessment
3. Describe the types and features of differentiated thyroid cancer
4. Explain the treatment and surveillance of papillary and follicular thyroid cancer
5. Describe medullary thyroid carcinoma and its genetic basis
6. Explain anaplastic thyroid cancer and other thyroid malignancies
---
## Lecture Outline
### I. Thyroid Nodules - Overview
Thyroid nodules are exceedingly common findings that require systematic evaluation to identify the minority harboring malignancy. While most nodules are benign, the clinical challenge lies in efficiently risk-stratifying patients to avoid unnecessary interventions while not missing cancers that require treatment.
The epidemiology of thyroid nodules reveals their remarkable prevalence. Palpable nodules are detected in approximately 5% of the population, but thyroid ultrasound identifies nodules in 50-70% of adults, illustrating the gap between clinically apparent and incidentally discovered disease. Women are affected approximately four times more frequently than men. Prevalence increases with age, reaching over 50% in individuals older than 60 years. Despite their frequency, only 5-15% of thyroid nodules are malignant, making accurate risk stratification essential to avoid unnecessary surgery.
The differential diagnosis of thyroid nodules spans benign and malignant entities. Benign nodules (85-95% of all nodules) include colloid nodules (the most common type, representing areas of hyperplastic thyroid tissue), follicular adenomas (benign encapsulated tumors), thyroid cysts (simple or complex), and nodules within the context of thyroiditis. Malignant nodules (5-15%) include papillary thyroid carcinoma (the most common thyroid cancer), follicular carcinoma, medullary carcinoma, and anaplastic carcinoma.
Risk factors for malignancy help identify nodules requiring more aggressive evaluation. Age extremes (younger than 30 or older than 60 years) carry increased risk. Male sex increases the likelihood of malignancy in a nodule. Prior radiation exposure, particularly childhood neck irradiation, is a well-established risk factor. Family history of thyroid cancer or MEN2 syndrome increases concern. Clinical features suggesting malignancy include rapid nodule growth, fixation to surrounding structures suggesting invasion, associated lymphadenopathy suggesting metastasis, and hoarseness from recurrent laryngeal nerve involvement.
Initial evaluation of a thyroid nodule begins with history and physical examination focused on risk factors and clinical features. The next steps include measurement of serum TSH to assess thyroid function and thyroid ultrasound to characterize the nodule. If TSH is suppressed (suggesting a hyperfunctioning nodule), radioactive iodine uptake and scan should be performed, as "hot" nodules are rarely malignant.
Panel A: Epidemiologic data showing thyroid nodule prevalence rates with 5% palpable, 50-70% on ultrasound, and 5-15% malignancy rate displayed as a population pyramid. Panel B: Risk factors for malignancy organized as patient factors (age extremes, male sex, radiation history, family history) and clinical features (rapid growth, fixation, lymphadenopathy, hoarseness) in color-coded categories. Panel C: Initial workup pathway flowchart showing history and physical examination leading to TSH measurement with a branch for suppressed TSH directing to RAI scan. Panel D: Thyroid ultrasound decision node showing how ultrasound findings guide further evaluation including FNA biopsy based on nodule characteristics.
---
### II. Thyroid Ultrasound
Thyroid ultrasound is the primary imaging modality for characterizing thyroid nodules and assessing cancer risk. High-frequency transducers provide excellent resolution of thyroid anatomy, allowing detailed assessment of nodule features and cervical lymph nodes.
Indications for thyroid ultrasound include any palpable thyroid nodule, incidental findings on other imaging studies (CT, MRI, or PET), high-risk patients (radiation exposure, family history), and goiter evaluation to assess for nodules within enlarged glands. Ultrasound should be the first-line imaging study for thyroid evaluation, as CT and MRI offer no advantage for nodule characterization and iodinated contrast may delay radioiodine therapy if needed.
Suspicious ultrasound features increase the likelihood of malignancy and guide biopsy decisions. Hypoechogenicity (appearing darker than surrounding thyroid tissue) suggests solid tissue rather than colloid. Microcalcifications represent psammoma bodies, concentric laminated calcifications particularly associated with papillary carcinoma. Irregular or infiltrative margins suggest invasion beyond the nodule capsule. A taller-than-wide shape (anteroposterior dimension exceeding transverse dimension) suggests growth against tissue planes. Extrathyroidal extension indicates invasion into surrounding structures. Abnormal cervical lymph nodes with round shape, loss of fatty hilum, or cystic change suggest metastatic disease.
The Thyroid Imaging Reporting and Data System (TI-RADS) provides standardized risk stratification. ACR TI-RADS assigns points based on composition, echogenicity, shape, margin, and echogenic foci, generating a category that guides whether and at what size threshold biopsy should be performed. TR1 (benign) nodules have essentially no malignancy risk and require no biopsy. TR2 (not suspicious) nodules carry approximately 1.5% risk and typically require no biopsy. TR3 (mildly suspicious) nodules with 4.8% risk should be biopsied if 2.5 cm or larger. TR4 (moderately suspicious) nodules with 9.1% risk warrant biopsy at 1.5 cm or larger. TR5 (highly suspicious) nodules with 35% risk should be biopsied at 1 cm or larger.
Lymph node evaluation is an essential component of thyroid ultrasound. Suspicious features in cervical lymph nodes include round shape (loss of the normal reniform configuration), absence of the fatty hilum (normally seen as a hyperechoic central region), hyperechogenicity or solid appearance, calcifications suggesting metastatic papillary cancer, and cystic areas from necrotic metastatic deposits. Lateral cervical compartment (levels II-IV) involvement is particularly concerning for papillary carcinoma metastases.
Panel A: Side-by-side ultrasound images comparing benign nodule features (isoechoic, smooth margins, wider-than-tall, comet-tail artifacts) versus suspicious features (hypoechoic, irregular margins, microcalcifications, taller-than-wide). Panel B: ACR TI-RADS classification table showing categories TR1 through TR5 with point assignments, malignancy risk percentages, and size thresholds for biopsy in color-coded format. Panel C: Lymph node ultrasound assessment comparing normal nodes (reniform shape, fatty hilum present) versus suspicious nodes (round shape, loss of hilum, calcifications, cystic areas). Panel D: Annotated ultrasound image demonstrating key measurement techniques including anteroposterior and transverse dimensions for taller-than-wide assessment.
---
### III. Fine-Needle Aspiration (FNA)
Fine-needle aspiration biopsy is the cornerstone diagnostic procedure for thyroid nodules, providing cytologic material for risk stratification. The technique involves ultrasound-guided sampling using a thin needle, typically without local anesthesia, allowing same-day outpatient evaluation.
Indications for FNA are determined by nodule size and TI-RADS category. Highly suspicious nodules (TI-RADS 5) should be biopsied at 1 cm or larger. Moderately suspicious nodules (TI-RADS 4) warrant biopsy at 1.5 cm or larger. Mildly suspicious nodules (TI-RADS 3) should be biopsied at 2.5 cm or larger. Any nodule with suspicious associated lymph nodes should undergo biopsy regardless of size. An important exception applies to hyperfunctioning ("hot") nodules on radioiodine scan, which are rarely malignant and do not require FNA.
The Bethesda System for Reporting Thyroid Cytopathology provides standardized classification with associated malignancy risks and management recommendations. Category I (Non-diagnostic/Unsatisfactory) indicates insufficient cellular material, with 5-10% implied malignancy risk; repeat FNA is recommended. Category II (Benign) findings such as colloid nodule or thyroiditis carry 0-3% malignancy risk; clinical follow-up with ultrasound surveillance is appropriate. Category III (Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance, or AUS/FLUS) represents intermediate cytology with 10-30% malignancy risk; options include repeat FNA, molecular testing, or lobectomy. Category IV (Follicular Neoplasm/Suspicious for Follicular Neoplasm, or FN/SFN) carries 25-40% malignancy risk; molecular testing or diagnostic lobectomy is recommended, as cytology alone cannot distinguish follicular adenoma from carcinoma. Category V (Suspicious for Malignancy) has 50-75% malignancy risk; lobectomy or total thyroidectomy is indicated. Category VI (Malignant) confirms cancer with 97-99% certainty; surgery is indicated.
Molecular testing has transformed the management of indeterminate cytology (Bethesda III and IV). Tests such as Afirma Gene Expression Classifier, ThyroSeq, and others analyze genetic and expression patterns to help "rule out" malignancy (high negative predictive value) or "rule in" malignancy (high positive predictive value). Benign molecular results in Bethesda III/IV nodules may allow surveillance rather than diagnostic surgery. Suspicious molecular results strengthen the indication for surgery. Specific mutations such as BRAF V600E virtually confirm papillary carcinoma.
Panel A: FNA technique illustration showing ultrasound-guided needle placement into a thyroid nodule with transducer positioning and needle trajectory. Panel B: Bethesda classification system displayed as a six-category table with category name, typical cytologic findings, malignancy risk percentage, and recommended management for each category (I through VI). Panel C: Pie charts showing malignancy risk distribution for each Bethesda category from non-diagnostic (5-10%) through malignant (97-99%). Panel D: Molecular testing integration flowchart showing Bethesda III/IV cytology branching to molecular testing, with benign results directing to surveillance and suspicious results directing to surgery.
---
### IV. Papillary Thyroid Carcinoma
Papillary thyroid carcinoma (PTC) is the most common thyroid malignancy, characterized by distinctive histologic features and generally excellent prognosis. Understanding its pathology, variants, and spread patterns informs treatment and surveillance strategies.
The epidemiology of PTC reflects its dominance among thyroid malignancies. It accounts for 80-85% of all thyroid cancers. PTC can occur at any age but peaks between 30-50 years. Women are affected approximately three times more frequently than men. The prognosis is excellent, with greater than 95% 10-year survival for most patients.
Pathologic features of PTC center on distinctive nuclear characteristics that allow diagnosis even in the absence of papillary architecture. The nuclei appear enlarged, overlapping, and pale with a ground-glass ("Orphan Annie eye") appearance due to chromatin clearing. Nuclear grooves (longitudinal indentations) and intranuclear pseudoinclusions (cytoplasmic invaginations) are diagnostic features. Psammoma bodies—concentric, laminated calcifications—are present in approximately 50% of cases and are essentially pathognomonic when seen in lymph nodes. Papillary architecture (finger-like projections with fibrovascular cores) is common but not required for diagnosis. Multifocal disease occurs frequently, and spread occurs preferentially via lymphatic channels rather than hematogenously.
Several variants of PTC have distinct clinical implications. Classical PTC represents the most common pattern with typical features. Follicular variant of PTC shows follicular architecture but with papillary nuclear features, and diagnosis requires careful evaluation to distinguish from follicular carcinoma. The non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) is now classified as low-risk and not called "carcinoma." Tall cell variant (cells >3 times taller than wide comprising >50% of tumor) behaves more aggressively with higher recurrence rates. Diffuse sclerosing variant affects young patients with bilateral, diffuse involvement but maintains good prognosis. Hobnail variant with cells bulging into follicular lumens behaves more aggressively.
Risk factors for PTC include prior radiation exposure (particularly childhood neck irradiation, with risk proportional to dose) and certain genetic alterations. RET/PTC chromosomal rearrangements occur in radiation-induced cancers and sporadic cases. BRAF V600E mutation is the most common molecular alteration (40-50% of cases), associated with more aggressive behavior and potential therapeutic target. Family history confers a small increased risk, though most PTC is sporadic.
Panel A: Diagnostic nuclear features of papillary thyroid carcinoma in illustrated microscopy views showing ground-glass nuclei with clearing, nuclear grooves with arrow annotations, intranuclear pseudoinclusions, and psammoma bodies as concentric calcifications. Panel B: Comparison table of major PTC variants including classical, follicular variant, tall cell, and diffuse sclerosing with relative aggressiveness indicated by color gradient. Panel C: Lymphatic spread pattern diagram showing primary thyroid tumor with arrows to cervical lymph node chain involvement contrasted with less common hematogenous dissemination route. Panel D: Molecular genetics panel illustrating BRAF V600E mutation (40-50% of cases) and RET/PTC rearrangement associations with their clinical significance.
---
### V. Follicular Thyroid Carcinoma
Follicular thyroid carcinoma (FTC) is the second most common differentiated thyroid cancer, distinguished from follicular adenoma only by histologic evidence of invasion. Its distinct biology, spread pattern, and diagnostic challenges differentiate it from papillary carcinoma.
The epidemiology of FTC shows it accounts for 10-15% of thyroid cancers. Peak incidence occurs at ages 40-60 years, somewhat older than papillary carcinoma. Women are more commonly affected than men. The overall prognosis is good, with approximately 90% 10-year survival, though somewhat lower than papillary carcinoma.
Pathologic features of FTC require demonstration of invasion to distinguish from benign follicular adenoma—a distinction that cannot be made on FNA cytology. The tumor shows follicular architecture without the nuclear features of papillary carcinoma. Capsular invasion (tumor penetrating through the fibrous capsule) and/or vascular invasion (tumor within blood vessel lumens) are required for diagnosis. Minimally invasive FTC demonstrates only capsular invasion and carries excellent prognosis. Widely invasive FTC shows vascular invasion and behaves more aggressively with higher metastatic potential.
The spread pattern of FTC differs fundamentally from papillary carcinoma. Hematogenous spread is the preferred route, with metastases occurring to lung and bone. Lymphatic spread to cervical lymph nodes is much less common than in papillary carcinoma. Bone metastases in FTC are characteristically lytic, in contrast to the sclerotic metastases more common in other tumors.
Hürthle cell carcinoma (oncocytic carcinoma) represents a distinct entity. It is characterized by oncocytic cells with abundant eosinophilic, granular cytoplasm due to packed mitochondria. Hürthle cell carcinoma is now classified separately from conventional FTC. It tends to behave more aggressively and often does not concentrate radioactive iodine, limiting treatment options.
Molecular alterations in FTC include RAS mutations (occurring in 40-50% of cases) and PAX8-PPARγ gene fusion (occurring in approximately 30% of cases), which can be detected on molecular testing of FNA specimens.
Panel A: Cross-sectional views comparing follicular adenoma (intact capsule) versus follicular carcinoma (capsular invasion and vascular invasion with tumor within blood vessels), with annotation explaining why FNA cannot distinguish the two. Panel B: Comparison of minimally invasive FTC (capsular invasion only, excellent prognosis) versus widely invasive FTC (vascular invasion, higher metastatic potential, worse prognosis). Panel C: Hematogenous spread pattern diagram showing primary thyroid tumor with arrows indicating preferential metastasis to lung and bone displayed as lytic lesions, contrasted with the lymphatic route typical of papillary carcinoma. Panel D: Inset microscopy view of Hurthle cells showing abundant eosinophilic granular cytoplasm from packed mitochondria with distinct oncocytic morphology.
---
### VI. Treatment of Differentiated Thyroid Cancer
Treatment of differentiated thyroid cancer (DTC), encompassing papillary and follicular carcinoma, involves a multimodal approach tailored to disease extent and risk stratification. Surgery forms the cornerstone, with radioactive iodine and TSH suppression providing adjuvant therapy in selected patients.
Surgical management is determined by tumor characteristics and extent of disease. Lobectomy (removal of one thyroid lobe with isthmus) is appropriate for low-risk tumors: unifocal tumors less than 4 cm without extrathyroidal extension or lymph node metastases. Total thyroidectomy is indicated for tumors larger than 4 cm, multifocal disease, extrathyroidal extension, lymph node metastases, distant metastases, or patient preference for definitive treatment. Central neck dissection (removal of lymph nodes in level VI) is performed when lymph nodes are clinically positive. Lateral neck dissection (levels II-V) is indicated for suspicious or confirmed lateral compartment lymph node involvement.
Radioactive iodine (RAI) ablation with I-131 serves multiple purposes after total thyroidectomy: ablating residual normal thyroid tissue (remnant ablation), treating known or suspected residual disease (adjuvant therapy), and treating metastatic disease. RAI is not indicated for low-risk papillary cancers smaller than 1 cm without adverse features. RAI should be considered for intermediate-risk patients. RAI is recommended for high-risk patients and those with distant metastases. Preparation requires TSH stimulation through either thyroid hormone withdrawal or recombinant human TSH (rhTSH) administration to enhance radioiodine uptake.
TSH suppression using levothyroxine reduces DTC recurrence by minimizing the growth stimulus from TSH. The degree of suppression is based on risk stratification. High-risk patients require TSH less than 0.1 mIU/L initially. Intermediate-risk patients should maintain TSH between 0.1-0.5 mIU/L. Low-risk patients with excellent response can maintain TSH in the normal range (0.5-2.0 mIU/L). Patients in remission may have TSH allowed into the normal range.
The American Thyroid Association (ATA) risk stratification guides treatment intensity. Low-risk disease includes intrathyroidal tumors with no more than 5 small lymph node metastases (each less than 0.2 cm). Intermediate-risk disease includes aggressive histologic subtypes, minor extrathyroidal extension, more than 5 lymph node metastases, or vascular invasion. High-risk disease includes gross extrathyroidal extension, incomplete resection, distant metastases, or elevated postoperative thyroglobulin suggesting residual disease.
Panel A: Surgical decision-making flowchart showing lobectomy criteria (unifocal, less than 4 cm, no extrathyroidal extension, no lymph node metastases) versus total thyroidectomy indications (greater than 4 cm, multifocal, extension, nodes, distant metastases). Panel B: RAI therapy indications organized by ATA risk category (low, intermediate, high) with dosing considerations and preparation requirements including TSH stimulation methods. Panel C: TSH suppression target sliding scale showing high-risk (less than 0.1 mIU/L), intermediate-risk (0.1-0.5 mIU/L), low-risk (0.5-2.0 mIU/L), and remission (normal range) categories. Panel D: ATA risk stratification sidebar listing criteria for low-risk, intermediate-risk, and high-risk disease with corresponding treatment intensity recommendations.
---
### VII. Surveillance of Differentiated Thyroid Cancer
Long-term surveillance of differentiated thyroid cancer aims to detect recurrence while minimizing unnecessary testing in patients with excellent prognosis. Thyroglobulin measurement and neck ultrasound form the foundation of surveillance.
Thyroglobulin (Tg) serves as the primary tumor marker for DTC surveillance. Thyroglobulin is produced only by thyroid tissue (normal or malignant), so after total thyroidectomy with or without RAI ablation, Tg should become undetectable or very low. Persistently detectable or rising Tg suggests residual or recurrent disease. Tg antibodies (TgAb) can interfere with Tg assays, causing falsely low results in immunometric assays, and their trend should be followed as a surrogate marker. Stimulated Tg measurement (after TSH elevation from withdrawal or rhTSH) has higher sensitivity than suppressed Tg, detecting smaller amounts of thyroid tissue.
Neck ultrasound surveillance examines the thyroid bed and central and lateral cervical lymph node compartments. Initial surveillance occurs 6-12 months postoperatively, with subsequent frequency determined by risk status. Findings prompting intervention include suspicious thyroid bed masses or lymph nodes with features such as round shape, loss of fatty hilum, calcifications, or cystic change. Ultrasound-guided FNA can confirm recurrence when findings are equivocal.
Radioiodine scanning plays a more limited surveillance role than in the past. Diagnostic whole-body scan may be performed post-ablation to assess completeness. Scanning may be indicated when Tg is elevated but anatomic imaging is negative, to identify iodine-avid metastatic disease. Post-therapy scans after RAI treatment may reveal additional metastases through the higher sensitivity afforded by therapeutic doses.
Response to therapy assessment categorizes patients' disease status and guides ongoing management. Excellent response indicates negative imaging and Tg less than 0.2 ng/mL on suppression or less than 1 ng/mL stimulated, and these patients may have reduced surveillance intensity. Biochemical incomplete response shows abnormal Tg without anatomic correlate; continued surveillance and possible empiric RAI are options. Structural incomplete response indicates imaging evidence of persistent or recurrent disease; treatment options include surgery, RAI, or targeted therapy. Indeterminate response shows non-specific findings; continued surveillance is warranted.
Management of recurrence depends on disease characteristics. Locoregional recurrence (thyroid bed or lymph nodes) is best treated with surgical resection if feasible. RAI therapy is appropriate for iodine-avid recurrence. RAI-refractory disease (disease that does not concentrate iodine or progresses despite RAI) may benefit from tyrosine kinase inhibitors such as lenvatinib or sorafenib.
Panel A: Thyroglobulin monitoring graph showing expected post-thyroidectomy trajectory declining to undetectable levels, with threshold lines indicating levels of concern and annotation explaining TgAb interference with assay interpretation. Panel B: Response-to-therapy categories displayed in a four-quadrant format with excellent response (negative imaging, low Tg), biochemical incomplete (abnormal Tg, negative imaging), structural incomplete (imaging evidence of disease), and indeterminate (nonspecific findings). Panel C: Recurrence management algorithm based on iodine avidity showing surgery for resectable locoregional disease, RAI for iodine-avid metastases, and TKIs (lenvatinib, sorafenib) for RAI-refractory disease. Panel D: Neck ultrasound surveillance timeline showing initial evaluation at 6-12 months postoperatively with subsequent frequency determined by risk category and response assessment.
---
### VIII. Medullary Thyroid Carcinoma
Medullary thyroid carcinoma (MTC) is a neuroendocrine tumor arising from parafollicular C cells, fundamentally distinct from differentiated thyroid cancers in its biology, markers, genetics, and management. Recognition of hereditary forms enables life-saving intervention in at-risk family members.
The epidemiology of MTC shows it accounts for 3-5% of thyroid cancers. It arises from parafollicular C cells, which produce calcitonin. Approximately 75% of cases are sporadic, while 25% are hereditary due to germline RET mutations. The prognosis is intermediate between differentiated and anaplastic thyroid cancer.
Clinical features of MTC at presentation typically include a thyroid nodule, though some patients present with symptoms from calcitonin or other hormone secretion, including diarrhea from gut hypermotility. Early lymph node involvement is common. Calcitonin serves as a highly sensitive and specific tumor marker; levels correlate with tumor burden and are used for diagnosis and surveillance. Carcinoembryonic antigen (CEA) is also elevated and has prognostic significance, with rapidly rising CEA suggesting dedifferentiation.
Hereditary forms of MTC occur in the context of Multiple Endocrine Neoplasia type 2 (MEN2), caused by activating germline mutations in the RET proto-oncogene. MEN2A includes MTC (95% penetrance), pheochromocytoma (50%), and primary hyperparathyroidism (20-30%). MEN2B includes MTC (100% penetrance, earliest and most aggressive), pheochromocytoma (50%), marfanoid body habitus, and mucosal neuromas (lips, tongue, conjunctivae). Familial MTC (FMTC) is now generally considered a variant of MEN2A with MTC only. The specific RET codon affected predicts phenotype and aggressiveness, guiding timing of prophylactic thyroidectomy.
Diagnosis of MTC involves measurement of calcitonin (elevated; diagnostic and correlates with tumor burden), CEA (elevated; prognostic), FNA cytology with calcitonin measurement in needle washout fluid, and RET genetic testing, which should be performed in all MTC patients to identify hereditary cases. If a RET mutation is identified, at-risk family members should be tested.
Treatment of MTC differs from DTC because MTC does not concentrate radioiodine (C cells lack the sodium-iodide symporter). Total thyroidectomy is always indicated. Central neck dissection is routinely performed given high rates of nodal involvement. Lateral neck dissection is performed when nodes are involved. Radioactive iodine has no role in MTC. For advanced or metastatic disease, tyrosine kinase inhibitors targeting RET (such as vandetanib and cabozantinib) have demonstrated efficacy. Selective RET inhibitors (selpercatinib and pralsetinib) show remarkable responses in RET-mutant tumors.
Screening in MEN2 families is potentially life-saving. Genetic testing identifies RET mutation carriers. Prophylactic thyroidectomy is recommended based on mutation-specific risk: infancy for highest-risk mutations (MEN2B), early childhood for high-risk mutations (certain MEN2A codons), and can potentially be delayed in some lower-risk MEN2A mutations. Annual screening for pheochromocytoma (plasma metanephrines) and hyperparathyroidism (calcium) should be performed in mutation carriers.
Panel A: C cell origin diagram showing parafollicular C cells within the thyroid gland with calcitonin secretion pathway and calcitonin/CEA marker measurement levels. Panel B: MEN2 syndrome comparison table showing MEN2A (MTC, pheochromocytoma, hyperparathyroidism), MEN2B (MTC, pheochromocytoma, marfanoid habitus, mucosal neuromas), and FMTC with penetrance rates for each component. Panel C: RET proto-oncogene schematic illustrating codon-specific mutations with corresponding risk levels and recommended timing of prophylactic thyroidectomy. Panel D: Treatment algorithm showing total thyroidectomy with central neck dissection as primary treatment, absence of RAI role, and TKIs/selective RET inhibitors (selpercatinib, pralsetinib) for advanced disease with screening protocol for mutation carriers.
---
### IX. Anaplastic Thyroid Carcinoma
Anaplastic thyroid carcinoma (ATC) is an undifferentiated malignancy representing the most aggressive form of thyroid cancer. Despite advances in therapy, prognosis remains poor, and management focuses on disease control and palliation for most patients.
The features of ATC distinguish it from other thyroid cancers. It accounts for only 1-2% of thyroid cancers but causes a disproportionate number of thyroid cancer deaths. ATC typically affects elderly patients older than 65 years. It is characterized by extremely aggressive behavior with rapid local invasion and distant metastasis. The prognosis is dismal, with median survival of only 3-5 months.
Clinical presentation reflects the aggressive biology. Patients describe rapidly enlarging neck mass, often over just weeks. Local invasion of trachea, esophagus, and major vessels causes compressive and invasive symptoms. Dyspnea occurs from tracheal involvement, dysphagia from esophageal invasion, and hoarseness from recurrent laryngeal nerve involvement. Distant metastases to lungs and other sites are common at diagnosis.
Pathologic features of ATC reflect its dedifferentiated nature. ATC may arise de novo or, commonly, from dedifferentiation of a preexisting differentiated thyroid cancer. Histologically, it shows highly pleomorphic cells with giant cells, spindle cells, or squamoid morphology. Thyroid-specific markers (thyroglobulin, TTF-1) are often lost, complicating diagnosis. Molecular alterations include BRAF mutations (in 40-50% of cases), RAS mutations, and TP53 mutations.
Treatment of ATC is challenging given the typically advanced stage at diagnosis. Surgery is performed if the tumor is resectable, which is rare. External beam radiation therapy provides local control and palliation. Conventional chemotherapy with doxorubicin-based regimens has limited benefit. Targeted therapy has transformed outcomes for patients with specific mutations: dabrafenib plus trametinib (BRAF/MEK inhibitors) achieve remarkable responses in BRAF V600E-mutant ATC, and this combination has become standard for BRAF-mutant disease. Immunotherapy with checkpoint inhibitors is under investigation. Palliative care is often the primary focus given the overall prognosis.
Emergent management may be required for airway compromise. Tracheostomy may be needed for impending airway obstruction. Radiation can reduce tumor bulk. Early integration of palliative care services supports quality of life.
Panel A: Clinical presentation of anaplastic thyroid carcinoma showing elderly patient with rapidly enlarging neck mass and labeled symptoms of local invasion including dyspnea, dysphagia, and hoarseness from recurrent laryngeal nerve involvement. Panel B: Pathologic features showing undifferentiated cells with pleomorphic, giant cell, and spindle cell morphology, annotated with loss of thyroid markers (thyroglobulin, TTF-1) and key molecular alterations (BRAF, RAS, TP53). Panel C: Treatment algorithm showing resection if possible, external beam radiation for local control, and molecular testing decision point leading to dabrafenib/trametinib for BRAF V600E-mutant disease. Panel D: Prognosis curve showing median survival of 3-5 months with comparison of outcomes for BRAF-mutant patients receiving targeted therapy versus conventional treatment.
---
### X. Other Thyroid Conditions
Beyond the major thyroid carcinomas, several other thyroid lesions require recognition and appropriate management. These include primary thyroid lymphoma, metastatic disease to the thyroid, thyroglossal duct anomalies, and multinodular goiter.
Primary thyroid lymphoma most commonly presents as diffuse large B-cell lymphoma, though other types including MALT lymphoma occur. A strong association exists with Hashimoto's thyroiditis, which is present in the majority of cases. Patients present with a rapidly enlarging goiter, often with compressive symptoms. Diagnosis requires tissue biopsy, and FNA may suggest lymphoma but core or excisional biopsy is often needed for classification. Treatment is chemotherapy with or without radiation therapy rather than surgery. MALT lymphomas may be indolent and localized, responsive to local therapy.
Metastases to the thyroid from non-thyroidal malignancies occur primarily in patients with widespread metastatic disease. The most common primary sites include kidney (renal cell carcinoma, the most common source), breast, lung, and melanoma. Metastases may present as new thyroid nodules in patients with known malignancy or, less commonly, as the first manifestation of an occult primary. FNA with appropriate immunohistochemical staining can confirm metastatic origin. Treatment depends on the primary cancer and overall disease extent.
Thyroglossal duct cyst represents a remnant of the thyroglossal duct, the embryologic path of thyroid descent from the foramen cecum at the base of the tongue to its final position. Cysts present as midline neck masses that characteristically move with swallowing and tongue protrusion. Approximately 1% of thyroglossal duct cysts harbor papillary thyroid carcinoma. Treatment is the Sistrunk procedure, which involves excision of the cyst along with the central portion of the hyoid bone and tissue to the base of the tongue to prevent recurrence.
Multinodular goiter represents thyroid enlargement with multiple nodules. It may be nontoxic (euthyroid) or toxic (producing hyperthyroidism from autonomous nodules). Nontoxic goiters may cause mass effect symptoms including dysphagia, dyspnea, or cosmetic concerns. Each nodule should be evaluated according to standard guidelines, with FNA of nodules meeting criteria. Management options include observation for stable, asymptomatic goiter; surgery for compressive symptoms, suspected malignancy, or cosmetic concerns; and radioactive iodine for toxic multinodular goiter.
Panel A: Thyroid lymphoma presentation showing rapid goiter enlargement in a patient with Hashimoto thyroiditis history, with treatment pathway indicating chemotherapy with or without radiation. Panel B: Metastases to thyroid with icons representing common primary sources (kidney, breast, lung, melanoma) and FNA with immunohistochemical staining as the diagnostic approach. Panel C: Thyroglossal duct cyst showing midline neck location, embryologic descent pathway from foramen cecum, movement with tongue protrusion, and Sistrunk procedure excision including central hyoid bone. Panel D: Multinodular goiter comparing nontoxic (euthyroid, mass effect symptoms) versus toxic (hyperthyroid, autonomous nodules) variants with management options including observation, surgery, and radioactive iodine.
---
## Summary
Thyroid nodules are common (50-70% of adults on ultrasound) with 5-15% malignancy rate. Evaluation involves TSH measurement and thyroid ultrasound, with FNA based on TI-RADS risk stratification. The Bethesda classification guides management of cytologic findings, with molecular testing helping refine indeterminate categories.
Papillary thyroid carcinoma accounts for 80% of thyroid cancers and is characterized by distinctive nuclear features, lymphatic spread, and excellent prognosis. Follicular thyroid carcinoma requires demonstration of capsular or vascular invasion for diagnosis and spreads hematogenously to lung and bone.
Treatment of differentiated thyroid cancer involves surgery (lobectomy or total thyroidectomy based on risk factors), radioactive iodine for intermediate and high-risk patients, and TSH suppression tailored to disease status. Surveillance relies on thyroglobulin measurement and neck ultrasound.
Medullary thyroid carcinoma arises from C cells, produces calcitonin, and is hereditary in 25% (MEN2 with RET mutations). RET genetic testing is essential for all patients, enabling prophylactic thyroidectomy in mutation carriers.
Anaplastic thyroid carcinoma is highly aggressive with median survival of 3-5 months. BRAF V600E-mutant tumors may respond dramatically to targeted therapy with dabrafenib and trametinib.
---
## Key Terms
| Term | Definition |
|------|------------|
| TI-RADS | Thyroid Imaging Reporting and Data System; standardized ultrasound-based risk stratification for thyroid nodules |
| Bethesda classification | Standardized cytology reporting system for thyroid FNA with six diagnostic categories |
| Papillary thyroid carcinoma | Most common thyroid cancer characterized by distinctive nuclear features and papillary architecture |
| Follicular thyroid carcinoma | Thyroid cancer diagnosed by demonstration of capsular or vascular invasion |
| Medullary thyroid carcinoma | Neuroendocrine thyroid cancer arising from parafollicular C cells |
| Anaplastic thyroid carcinoma | Undifferentiated, highly aggressive thyroid malignancy |
| Thyroglobulin | Tumor marker for surveillance of differentiated thyroid cancer |
| RET mutation | Oncogenic mutation in the RET proto-oncogene causing hereditary MTC and MEN2 |
---
*This content is subject to the [MIT License](https://opensource.org/licenses/MIT). © 2024–2026 Hibbert School of Medicine.*